restore heart function after myocardial ischemia and heart attacks. Summa Biotech also builds advanced multicellular 3D cardiac tissue models to evaluate RNA-based therapies and vector delivery strategies. In addition, it develops AI tools to support clinical trial enrichment and biomarker verification for RNA therapies. The organization collaborates with academic and industry partners on inducible, cardiac-specific AAV vector platforms and other technologies to improve safety and control of gene therapies for heart disease.